Document is current
Any future updates will be listed below
-
Authors
Kerola, Anne M. http://orcid.org/0000-0003-2257-3291
Semb, Anne Grete http://orcid.org/0000-0003-2730-2853
Juonala, Markus http://orcid.org/0000-0001-9498-364X
Palomäki, Antti http://orcid.org/0000-0002-8835-8116
Rautava, Päivi http://orcid.org/0000-0003-2795-1327
Kytö, Ville http://orcid.org/0000-0002-4521-1093
-
Funding
Funding for this research was provided by:
Sydäntutkimussäätiö
Paulon Säätiö
Suomen Kulttuurirahasto
the Finnish Governmental VTR-funding
- License Information
-
More Information
Article History
Received: 20 July 2022
Accepted: 23 August 2022
First Online: 6 September 2022
Declarations
:
: Please see “InternalRef removed” under Methods.
: Not applicable.
: AK: speaker fees from Boehringer-Ingelheim and Sanofi, advisory board fees from Pfizer, Gilead, and Boehringer-Ingelheim, and congress sponsorship from Pfizer, Celgene, UCB Pharma, Mylan, and Roche. AGS: speaker honoraria and/or consulting fees from Pfizer, Amgen, Sanofi, Novartis, Bayer, AbbVie, and Lilly, unrestricted research grant from Lilly. MJ: speaker fees from Boehringer-Ingelheim, AstraZeneca, and Amgen. AP: consulting fees from Pfizer, AbbVie, and Amgen, lecture fees from MSD, Pfizer, and Sanofi, and travel expenses from Bristol Myers Squib and Novartis. PR: None. VK: scientific consultancy fees from AstraZeneca, speaker fee from Bayer, and travel grants and congress sponsorships from Bayer and Biotronic.
